Social Burden and Goals of Therapy for Patients with Bronchiectasis
A medical professional addresses the social aspects of bronchiectasis, emphasizing patients' embarrassment due to productive coughing in public spaces like grocery stores and churches, as well as the psychological challenges of planning travel and vacations due to the unpredictability of exacerbations, which can lead to social isolation.
Opinion
Video
Social Burden and Goals of Therapy for Patients with Bronchiectasis
A medical professional addresses the social aspects of bronchiectasis, emphasizing patients' embarrassment due to productive coughing in public spaces like grocery stores and churches, as well as the psychological challenges of planning travel and vacations due to the unpredictability of exacerbations, which can lead to social isolation.
EP: 1.Overview of Bronchiectasis
EP: 2.Prognosis For Patients Diagnosed With Bronchiectasis
EP: 3.Indicators Leading to Bronchiectasis Testing and Diagnosis
EP: 4.Complications Associated With Bronchiectasis
EP: 5.Current Treatment Options For Bronchiectasis
EP: 6.Respiratory and Physical Therapists Contributing to Comprehensive Bronchiectasis Care
EP: 7.Key Areas of Research and Emerging Therapies In Bronchiectasis Treatment
EP: 8.Diagnosing and Understanding the Pathogenesis of Bronchiectasis
EP: 9.Improving Long-Term Outlook: CT Scans and Underdiagnosis of Bronchiectasis
EP: 10.Bronchiectasis Exacerbation Management
EP: 11.Social Burden and Goals of Therapy for Patients with Bronchiectasis
EP: 12.Patient Specific Factors: Guiding Treatment in Bronchiectasis
EP: 13.Individualized Therapy for Specific Infections Associated with Bronchiectasis
EP: 14.Other Challenges With Bronchiectasis and Key Takeaways
EP: 15.Identifying Bronchiectasis: Key Clinical Presentations to Consider
EP: 16.Differentiating Bronchiectasis from COPD and Understanding Exacerbations
EP: 17.Long-Term Impact of Bronchiectasis Exacerbations: Disease Progression, Patient Outcomes, and Economic Burden
EP: 18.Managing Bronchiectasis: Treatment Goals, Outcome Measures, and Clinical Decision Resources
EP: 19.Addressing Knowledge Gaps and Treatment Strategies in Bronchiectasis
EP: 20.Challenges and Future Directions in Bronchiectasis Management
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma
Five Years Later: Ongoing COVID-19 Challenges, Next Steps
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
5 Key FDA Approval Dates Mark a Milestone-Filled May
Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma
Five Years Later: Ongoing COVID-19 Challenges, Next Steps
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
5 Key FDA Approval Dates Mark a Milestone-Filled May